Cost-Effectiveness Analysis of Durvalumab in Limited-Stage Small Cell Lung Cancer in the United States
PURPOSESmall cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by poor prognosis. The ADRIATIC trial demonstrated significant survival benefits with durvalumab as maintenance therapy for limited-stage SCLC (LS-SCLC). However, the high cost of durvalumab necessitates an...
Shranjeno v:
| Principais autores: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Clinical Oncology
2025-12-01
|
| Serija: | JCO Global Oncology |
| Online dostop: | https://ascopubs.org/doi/10.1200/GO-25-00225 |
| Oznake: |
Brez oznak, prvi označite!
|